The global airway clearance devices system market is set to experience robust growth over the next decade. Valued at USD 624.5 million in 2023, the market is projected to expand at a compound annual growth rate (CAGR) of 6.2%, reaching an estimated USD 1,137.2 million by 2033.
This growth is primarily driven by the rising prevalence of respiratory diseases such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. The increasing awareness about the benefits of airway clearance devices in managing these conditions, along with technological advancements in device development, are key factors contributing to the market’s expansion.
When used in conjunction with respiratory therapy, airway clearance devices help patients with bronchiectasis, cystic fibrosis, and chronic obstructive pulmonary disease (COPD) by efficiently eliminating mucus and enhancing lung function. To mobilize and remove secretions from the airways, these devices use a variety of techniques, including mechanical percussion, oscillatory positive expiratory pressure (OPEP), and high-frequency chest wall oscillation (HFCWO).
Request Your Detailed Report Sample With Your Work Email:
https://www.futuremarketinsights.com/reports/sample/rep-gb-5230
In order to maximize outcomes and enhance the patient experience, stakeholders in the respiratory treatment sector are concentrating on innovation, education, and patient-centered care as the global healthcare landscape changes. Airway clearance medicine availability can be increased globally by manufacturers and healthcare providers addressing unmet requirements through investments in clinical evidence collecting, patient support programs, and research and development.
Key Drivers of Market Growth:
- Rising Prevalence of Respiratory Disorders: The increasing number of individuals diagnosed with cystic fibrosis, chronic obstructive pulmonary disease (COPD), and bronchiectasis is driving the demand for airway clearance devices.
- Technological Advancements: Medical device companies are continually innovating and developing more user-friendly and effective airway clearance devices. For instance, Project Fizzyo, a collaboration between Microsoft, Great Ormond Street Hospital, and University College London, gamifies cystic fibrosis treatment, making it more engaging for children.
- Improved Patient Outcomes: Airway clearance devices effectively remove mucus, leading to reduced lung infections and improved lung function for patients.
Competitive Landscape:
To increase their market share significantly, most businesses take part in joint research projects, market expansions, and strategic acquisitions. Allergan plc, Dymedso Inc., Electromed Inc., Ltd., General Physiotherapy Inc., Hill-Rom Holdings, Inc., International Biophysical Corporation, Koninklijke Philips N.V. (Philips), Monaghan Medical Corporation, Inc., PARI GmbH, and Thayer Medical are a few of the well-known companies in the global market for airway clearance devices.
Recent Developments:
- In May 2022, AbbVie, a research-based global biopharmaceutical company, announced that it has completed its acquisition of Allergan plc following receipt of regulatory approval from all government authorities required by the transaction agreement and approval by the Irish High Court.
- In 2021, Baxter International, a renowned MedTech leader, announced that it had completed the acquisition of Hillrom. Baxter paid US$ 156 in cash for each outstanding share of Hillrom common stock for a purchase price of US$ 10.5 million. Including the assumption of Hillrom’s outstanding debt obligations, the enterprise value of the transaction is about US$ 12.5 million
- Thayer Medical has introduced the Quake airway clearance device for people suffering from mucus-producing respiratory conditions. The product delivers comprehensive and convenient secretion clearance therapy that has an easy-to-use, portable, and handheld design.
- Monaghan Medical Corporation has added its oscillating positive expiratory pressure device named Aerobika. This helps in clearing the lungs and serves people with conditions like COPD, cystic fibrosis, and bronchitis
Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-5230
Key Segmentation:
By Product Type:
- Positive Expiratory Pressure
- Intrapulmonary Percussive Ventilation
- Oral High-Frequency Oscillation
- High-Frequency Chest Wall Oscillation
- Flutter
- Incentive Spirometry
By End User:
- Hospitals
- Clinics
- Ambulatory Surgical Centers
Key Regions Covered:
- North America
- The United States
- Canada
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Europe
- Germany
- The United Kingdom
- France
- Spain
- Russia
- Rest of Europe
- Japan
- Asia Pacific Excluding Japan
- China
- India
- Malaysia
- Singapore
- Australia
- Rest of Asia Pacific Excluding Japan (APEJ)
- The Middle East and Africa
- GCC Countries
- Israel
- South Africa
- The Middle East and Africa (MEA)
In-Depth Market Overview: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/5230
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube